In brief
- On August 13, the US health agency HRSA closed a public consultation on how to train staff and organize clinics that may one day offer psychedelic therapy.
- It received 59 responses from pharmaceutical labs, operators of existing legal programs in Oregon and Colorado, professional associations, and training centers.
- The consultation does not approve any drugs; it prepares the regulatory groundwork for the day the FDA authorizes the first one.
No classic psychedelic substance has yet received the green light from the FDA for any treatment. However, the administrative machinery that will decide how that therapy is applied, when it arrives, is already in motion. On July 14, the Health Resources and Services Administration (HRSA)—the US Department of Health agency tasked with bringing healthcare to rural areas and underserved populations—opened a public consultation to gather ideas on staff training and outpatient care models. The window closed on August 13 with 59 responses on the table.
Who responded and what they said
Among those who submitted comments are drug developers like Definium Therapeutics, associations such as the Association for Prescription Psychedelics, clinical management firms, operators of the only two state-level models already running in the US (the legal psilocybin programs in Oregon and Colorado), non-profits, professional boards, and facilitator training centers. The HRSA requested opinions on three specific areas: what training staff need before the session (screening, pre-interview), during clinical administration, and in post-session follow-up; how to integrate these treatments into community health centers, rural facilities, and certified mental health clinics designed to reach those who cannot currently afford private consultations; and what role technology, including artificial intelligence, can play in making these models sustainable at a larger scale.
The context: An order that accelerated the timeline
This consultation did not emerge from a vacuum. In April, a US government executive order instructed the FDA and other agencies to accelerate the review of psychedelic compounds for therapeutic purposes, and the HRSA is one piece of that mechanism: if a psychedelic drug is approved at some point, someone will have to decide who can administer it, with what training, and in what type of facility. The participation of operators from Oregon and Colorado makes sense; they are the only places in the country with years of real-world experience managing supervised psilocybin sessions outside of a clinical trial, and their practical experience is exactly the type of data a federal agency cannot generate on its own.
What it implies
A public consultation does not approve drugs or change any laws; it is a procedural step to collect opinions before drafting technical guidelines. However, it signals the direction of the debate in the US for the coming years, and that debate is significant: it will decide whether access to these therapies remains reserved for expensive private clinics or if it also reaches those who cannot afford them via community health centers. The HRSA has not yet published a summary of positions or a date for the final guidance, so for now, there are only questions on the table, not answers. It is worth following the process with caution: 59 comments from highly interested parties (companies, clinics, associations) do not equate to a decided policy, and the distance between a public consultation and an implemented regulation is usually long.
Source
- Psychedelic Alpha. Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI. Psychedelic Alpha, August 20, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
